New cocktail aims to tame aggressive lymphoma in the very elderly
NCT ID NCT04974216
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a combination of three drugs—tafasitamab, lenalidomide, and rituximab—in people aged 80 and older with untreated diffuse large B-cell lymphoma (DLBCL). The goal is to see if this gentler, chemotherapy-free regimen can shrink or eliminate tumors after three cycles of treatment. The study enrolled 71 participants and is no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tafasitamab, lenalidomide, and rituximab
What this could lead to
If successful, this combination could offer a gentler, effective treatment option for elderly patients with diffuse large B-cell lymphoma who cannot tolerate standard chemotherapy.
What could go wrong
This is a small, early-phase trial (71 patients) with no comparison group. The drugs may cause serious side effects, and the results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHP - Hôpital Saint Louis
Paris, France
-
Besancon University Hospital Center
Besançon, 25030, France
-
CH Saint Vincent de Paul
Lille, France
-
CHRU Mont Godinne
Yvoir, Belgium
-
CHRU de LILLE - Claude Huriez
Lille, France
-
CHU Brabois
Vandœuvre-lès-Nancy, France
-
CHU Helora
La Louvière, 7100, Belgium
-
CHU de Bordeaux - Hôpital Haut Lévêque
Bordeaux, France
-
CHU de Liège
Liège, Belgium
-
CHU de Nantes - Hôtel Dieu
Nantes, France
-
Centre Henri Becquerel
Rouen, France
-
Centre Hospitalier D Avignon
Avignon, France
-
Centre Hospitalier De La Cote Basque
Bayonne, France
-
Centre Hospitalier Departemental Vendee
La Roche-sur-Yon, France
-
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, France
-
Chu de Limoges - Hopital Dupuytren
Limoges, France
-
Clinique Universitaire Saint LUC
Brussels, Belgium
-
Grand Hopital De Charleroi
Charleroi, 6000, Belgium
-
Institut Bergonié - Bordeaux
Bordeaux, France
-
Institut de Cancérologie de la Loire Lucien Neuwirth
Saint-Priest-en-Jarez, 42270, France